ID: ALA3792620

Max Phase: Preclinical

Molecular Formula: C11H5I4NO4

Molecular Weight: 722.78

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CC(C(=O)O)N1C(=O)c2c(I)c(I)c(I)c(I)c2C1=O

Standard InChI:  InChI=1S/C11H5I4NO4/c1-2(11(19)20)16-9(17)3-4(10(16)18)6(13)8(15)7(14)5(3)12/h2H,1H3,(H,19,20)

Standard InChI Key:  BKFNZEOOHLSLFV-UHFFFAOYSA-N

Associated Targets(Human)

Casein kinase II 1406 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 722.78Molecular Weight (Monoisotopic): 722.6397AlogP: 3.17#Rotatable Bonds: 2
Polar Surface Area: 74.68Molecular Species: ACIDHBA: 3HBD: 1
#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 1.45CX Basic pKa: CX LogP: 4.68CX LogD: 1.15
Aromatic Rings: 1Heavy Atoms: 20QED Weighted: 0.22Np Likeness Score: -0.39

References

1. Ostrynska OV, Balanda AO, Bdzhola VG, Golub AG, Kotey IM, Kukharenko OP, Gryshchenko AA, Briukhovetska NV, Yarmoluk SM..  (2016)  Design and synthesis of novel protein kinase CK2 inhibitors on the base of 4-aminothieno[2,3-d]pyrimidines.,  115  [PMID:27017545] [10.1016/j.ejmech.2016.03.004]

Source